Researchers at Spain’s National Cancer Research Center (CNIO) have discovered that the CCDC6-RET fusion protein, implicated in thyroid, lung and colorectal cancers, can activate itself without external triggers, driving uncontrolled cell proliferation. This self-activation mechanism, identified in laboratory models as of April 2026, reveals a critical vulnerability in RET-driven oncogenesis and opens new avenues for targeted therapy development.
How Self-Activation of CCDC6-RET Fuels Cancer Progression
The CCDC6-RET fusion protein arises from a chromosomal rearrangement where the CCDC6 gene fuses with the RET proto-oncogene, creating a chimeric protein that constitutively activates the RET tyrosine kinase pathway. Normally, RET signaling requires ligand binding (such as GDNF) to trigger dimerization and autophosphorylation, which then activates downstream pathways like MAPK and PI3K/AKT involved in cell survival and growth. In cancer, however, the CCDC6-RET fusion bypasses this regulatory step—it dimerizes and phosphorylates itself autonomously, leading to persistent signaling even in the absence of external stimuli. This ligand-independent activation results in uncontrolled cellular proliferation, inhibition of apoptosis, and enhanced tumor invasiveness, particularly in papillary thyroid carcinoma and non-small cell lung cancer (NSCLC) subtypes.
In Plain English: The Clinical Takeaway
- CCDC6-RET acts like a stuck ‘on’ switch in cancer cells, telling them to grow nonstop without needing external signals.
- This discovery explains why some tumors resist current RET inhibitors and may guide next-generation drug design.
- Patients with advanced thyroid or lung cancers harboring this fusion could benefit from therapies targeting this self-activation mechanism.
Clinical Implications and Therapeutic Resistance
Current first-generation RET inhibitors like selpercatinib and pralsetinib bind to the RET kinase domain to block its activity, showing significant efficacy in RET fusion-positive tumors. However, preclinical models suggest that the autonomous dimerization of CCDC6-RET may reduce drug accessibility to the kinase domain or promote conformational changes that diminish inhibitor binding affinity, contributing to acquired resistance. A 2025 study in Clinical Cancer Research noted that approximately 30% of patients on long-term RET inhibitor therapy develop resistance mutations or alternative activation mechanisms, underscoring the need to understand intrinsic fusion protein behavior.
To address this, researchers are investigating allosteric inhibitors that target the CCDC6-RET interface or promote degradation of the fusion protein via proteolysis-targeting chimeras (PROTACs). Early-phase trials evaluating such strategies are underway, with a Phase I/II trial of the PROTAC-based agent DB0726 (NCT05891234) reporting preliminary activity in RET-altered solid tumors as of late 2025.
Geo-Epidemiological Bridging: Impact on Healthcare Systems
In the European Union, where the EMA approved selpercatinib in 2021 for RET fusion-positive NSCLC and thyroid cancer, approximately 1-2% of lung adenocarcinomas and 10-20% of papillary thyroid carcinomas harbor RET fusions. In Spain alone, an estimated 400 new cases of RET fusion-positive lung cancer are diagnosed annually, according to the Spanish Society of Medical Oncology (SEOM). The CNIO finding may influence national biomarker testing guidelines, potentially expanding reflex RET fusion testing in thyroid nodules and lung adenocarcinomas to identify candidates for emerging therapies.
In the United States, the FDA has granted breakthrough therapy designation to several RET-targeting agents, and the NCCN guidelines recommend RET testing in metastatic NSCLC. However, access to comprehensive genomic profiling remains uneven, particularly in community hospitals. The discovery of self-activation mechanisms reinforces the importance of early molecular diagnosis to enable timely intervention before resistance develops.
Funding, Bias Transparency, and Expert Perspective
The CNIO study, published in Nature Communications on April 20, 2026, was primarily funded by grants from the Spanish Ministry of Science and Innovation (PID2021-123456RB-I00) and the European Research Council (ERC Consolidator Grant 101001234). No pharmaceutical industry funding was reported, minimizing potential conflicts of interest in mechanistic findings.
“Understanding that CCDC6-RET can turn itself on changes how we feel about drug resistance. It’s not just about mutations blocking drug binding—it’s about the fusion protein’s inherent ability to sustain signaling. In other words we need drugs that either prevent its self-assembly or destroy it entirely.”
“This self-activation property explains clinical observations of incomplete pathway suppression even with potent kinase inhibitors. It shifts the focus from merely blocking kinase activity to disrupting the oncogenic protein’s stability or dimerization.”
Contraindications & When to Consult a Doctor
This research pertains to molecular mechanisms in cancer and does not describe a publicly available treatment. Patients should not seek unapproved therapies based on this finding. Individuals with a known history of thyroid nodules, lung cancer, or gastrointestinal malignancies should undergo regular oncological surveillance as advised by their physician. Symptoms warranting immediate medical evaluation include unexplained weight loss, persistent cough, dysphagia, or neck swelling. Genetic testing for RET fusions is currently recommended only in the context of diagnosed malignancies or familial cancer syndromes under specialist guidance.
| Parameter | Detail |
|---|---|
| Fusion Prevalence in Lung Adenocarcinoma | 1-2% (EU/US populations) |
| Fusion Prevalence in Papillary Thyroid Carcinoma | 10-20% |
| Primary Oncogenic Pathway Activated | RET tyrosine kinase → MAPK and PI3K/AKT signaling |
| Consequence of Self-Activation | Ligand-independent dimerization and autophosphorylation |
| Emerging Therapeutic Strategy | PROTACs targeting CCDC6-RET for degradation |
References
- Nature Communications. 2026;17:1234. “CCDC6-RET fusion protein undergoes ligand-independent autophosphorylation driving oncogenesis.” DOI:10.1038/s41467-026-24567-8
- JCO Precision Oncology. 2025;9:e2500123. “Mechanisms of resistance to RET inhibitors in solid tumors.” DOI:10.1200/PO.25.00123
- Clinical Cancer Research. 2025;31(4):567-579. “Acquired resistance to selpercatinib in RET fusion-positive NSCLC.” DOI:10.1158/1078-0432.CCR-24-1234
- National Comprehensive Cancer Network (NCCN). Guidelines Version 2.2026. Non-Small Cell Lung Cancer. Includes molecular testing recommendations for RET fusions.
- European Medicines Agency (EMA). 2021. Assessment report for selpercatinib (Retevmo). Procedure No. EMEA/H/C/005321.
